Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Google Secures Pentagon AI Deal for Classified Projects 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
SANTA MONICA, Calif., Feb. 16, 2016 -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that David D. Chang, M.D., Ph.D., Executive Vice President, Research and Development, and Chief Medical Officer, will participate in a fireside chat discussion at the 2016 RBC Capital Markets Global Healthcare Conference.
| Event: | 2016 RBC Capital Markets Global Healthcare Conference | |
| Date: | Tuesday, February 23, 2016 | |
| Time: | 4:05 PM Eastern Time | |
| Location: | New York, NY | |
A live audio webcast will be available on the Investors section of Kite’s website, www.kitepharma.com. A replay of the webcast will be available on the website for approximately 30 days.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
CONTACT: Greg Mann VP, Investor Relations [email protected] For Media: Justin Jackson Burns McClellan (212) 213-0006 [email protected]
